News coverage about AstraZeneca (NYSE:AZN) has been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. AstraZeneca earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.9327370663666 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news articles that may have impacted Accern’s scoring:

Several equities research analysts have recently commented on AZN shares. BMO Capital Markets set a $38.00 target price on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Wednesday, November 15th. Citigroup raised shares of AstraZeneca to a “buy” rating in a research report on Wednesday, October 18th. Sanford C. Bernstein reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Friday, September 22nd. Zacks Investment Research raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Finally, Cowen reaffirmed a “hold” rating and issued a $37.00 target price on shares of AstraZeneca in a research report on Tuesday, October 17th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $34.48.

Shares of AstraZeneca (AZN) traded up $0.35 during midday trading on Friday, reaching $35.44. 2,530,000 shares of the company were exchanged, compared to its average volume of 3,040,000. AstraZeneca has a one year low of $26.51 and a one year high of $35.92. The stock has a market cap of $88,530.00, a PE ratio of 25.31, a P/E/G ratio of 2.59 and a beta of 0.76. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings results on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.55. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The company had revenue of $6.23 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same period last year, the company posted $1.32 EPS. AstraZeneca’s revenue was up 9.4% on a year-over-year basis. research analysts anticipate that AstraZeneca will post 1.9 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact AstraZeneca (AZN) Share Price” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-astrazeneca-azn-share-price/1814547.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Insider Buying and Selling by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.